secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2026-04-20T23:59:59+00:00
Accession:  0001193125-26-164330
Event type: other
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 2.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio completes spin-off of First Tracks Biotherapeutics (TRAX); distribution effective April 20, 2026
--------------------------------------------------------------------------------

- Each ANAB shareholder received one TRAX share for each share held on record date April 6, 2026.
- First Tracks started trading on Nasdaq under ticker TRAX on April 20, 2026.
- AnaptysBio retains royalty management for dostarlimab (Jemperli) and imsidolimab from Vanda.
- First Tracks receives $100M cash, up to $35M in Vanda milestones, and clinical assets rosnilimab, ANB033, ANB101.
- Separation and Distribution Agreement allocates assets/liabilities between royalty management and biotech businesses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000119312526164330/0001193125-26-164330-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000119312526164330/d120122d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-164330

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer